Nerve damage repair agent hope

Max · 07-25-2005, 01:15 PM

KDI may help with Alzheimer's and other brain diseases

Scientists say they have discovered a protein that could be injected to repair damaged nerves and brain cells.

The protein, KDI tripeptide, works by blocking the harmful effects of a substance present in degenerative brain diseases and spinal cord injuries.

By blocking this substance, called glutamate, KDI prevents permanent cell death and helps the body heal itself.

The Finnish work from the University of Helsinki will be published online by the Journal of Neuroscience Research. Human trials So far the researchers have tested KDI in the lab on animals and nerve cells from humans.

http://news.bbc.co.uk/1/hi/health/4707023.stm

Jakstraw · 07-25-2005, 01:25 PM

Hold for release until 12:01 a.m. EDT Jul. 25.

The information in this press release is EMBARGOED until 12:01 a.m. EST, Monday, July 25. AScribe Newswire is providing the release in advance as a courtesy to the media.

ATTENTION: Medical, Science editors

New Study Reveals Potential New Treatment of Paralysis, Brain Disease; Research From Brain Laboratory at University of Helsinki Suggests Wide-Ranging Treatment Applications for Millions With Spinal Cord Injuries, Alzheimer's Disease, ALS, Other Debilitating Illnesses

HELSINKI, Finland, July 25 (AScribe Newswire) -- A study released today could reveal the key to treating nearly 140 million people worldwide who suffer from spinal cord injuries, Alzheimer's disease, ALS and other devastating neurological diseases.

The study, published in the online edition of the Journal of Neuroscience Research, shows how a protein called KDI tri-peptide (KDI) can block the harmful effects of a substance called glutamate that is present in all degenerative brain diseases and spinal cord injuries, causing permanent cell death and preventing the repair of damaged nerve connections. Glutamate is produced as part of the body's natural reaction to central nervous system damage.

In the new study, researchers at the Brain Laboratory at the University of Helsinki (www.brainlab.fi ) and at the Johnnie B. Byrd, Sr., Alzheimer's Center & Research Institute in Tampa, Fla., show KDI to be a potent and wide-ranging blocker of glutamate's damaging chemical processes. It therefore has a tremendous ability to protect the brain and spinal cord from cell death and even enable regrowth.

Human clinical trials are expected to begin as soon as next year. No toxic side effects have been seen in studies so far, and the Finnish researchers do not expect any since KDI occurs naturally in the human body, including in the central nervous system. An added advantage is that KDI can be easily synthesised, therefore avoiding the problems associated with human cell donation.

PARALYSIS REVERSAL IN RATS OFFERED CLUES TO WIDE-RANGING APPLICATIONS

The new findings follow from previous studies in which KDI, when injected into the spines of paralyzed rats, produced dramatic results. The rats were able to bear weight and walk again after only 3 months. Further laboratory experiments showed that KDI also had the ability to promote regrowth of nerves in damaged areas and to prevent brain cell death. These results paved the way for new research with human cells.

In the new study, Dr. Pdivi Liesi, M.D., Ph.D., and her research team applied KDI to human brain cells in the laboratory to see if KDI's extraordinary ability to prevent nerve cell death and promote regeneration could be connected to its unexpected effect on the glutamate system. The study concludes that KDI is able to block various forms of glutamate function - leading researchers to believe that it may have wide-ranging applications.

"The wider significance of this research is that KDI treatment may become the first natural and targeted therapy for people with central nervous system injuries resulting in paralysis and a range of diseases such as Alzheimer's and ALS, for which there are currently no cures," said Dr. Liesi, head of the Brain Laboratory and a former visiting scientist at the National Institutes of Health.

NEW APPROACH COULD FAST-TRACK TO REAL RESULTS

Dr. Liesi's long-term focused research has built upon an original discovery by George Martin, Ph.D., former scientific director for the National Institute on Aging at the National Institutes of Health. Dr. Martin first discovered the molecule known as laminin that KDI is derived from. Dr. Liesi identified laminin's role in the nervous system and was able to isolate KDI from the larger molecule. After intensive study of its effects in the central nervous system, she began to recognise KDI's enormous therapeutic potential.

"One of the wonderful things about this is that Dr. Liesi's discoveries are ready now for prime-time testing in patients. We do not have to go through a long drug development procedure that might take 10 years," said Dr. Martin. "This represents a new approach and one with considerable promise, particularly because it could be applied and tested rapidly with a variety of disorders. The ability to treat degenerative brain diseases and spinal cord injuries with a substance that naturally occurs in the body is revolutionary."

"I am excited by the potential clinical uses of KDI and by the prospect of clinical testing," said Dr. Victor Krauthamer, Ph.D., a former research collaborator of Dr. Liesi, speaking as an independent scientist. Dr. Krauthamer also is a research scientist at the U.S. Food and Drug Administration, Center for Devices and Radiological Health. "If these results play out in further trials, and there is a true treatment for a variety of currently untreatable neurological diseases, this could be one of the greatest discoveries in treating neurological conditions in the last 50 years."

Dr. Liesi conducts her current research in close collaboration with the Johnnie B. Byrd, Sr., Alzheimer's Center & Research Institute in Tampa, Fla. The Byrd Institute is dedicated to helping and coordinating research, as well as building national and international collaborations. The goal of this productive international collaboration is to transform research results into practical clinical applications as quickly as possible, delaying the disease's onset, and ultimately slowing or even halting the disease's progression. Visit http://www.floridaalz.org for more details about the Byrd Institute's ongoing efforts.

Details of Dr. Liesi's research and further information can be found at http://www.brainlab.fi, a site affiliated with the University of Helsinki. The University is one of the centers of excellence among universities in Europe, concentrating on high-level scientific research and researcher education. The results produced through the research and teaching carried out at the University are widely acclaimed worldwide

ip · 07-25-2005, 01:33 PM

Anybody know if this is a significant study? The descriptions are glowing, so of course that gives me hope.

Will this work for chronics?????

manouli · 07-25-2005, 01:49 PM

This is great news! Hey guys please tell me if you know that this will not only works when they apply it as soon after spinal cord injury? I want to try it right way. cross our fingers.manouli.

Sue Pendleton · 07-25-2005, 01:59 PM

"It therefore has a tremendous ability to protect the brain and spinal cord from cell death and even enable regrowth."

Sounds like it may be usable for chronic ailments. I mean even people with Alzheimer's have lost a lot upstairs before they are normally diagnosed. Even to just stop the damage in so many cases will make many lives so much better: ALS, MS, Alzheimers, new cord injuries. But it does sound promising for chronics.

Lindox · 07-25-2005, 02:29 PM

This is very interesting and exciting.

Looks to me though that a patient might have to take this for the rest of their lives in the disease process types of problems..and maybe even in the acute SCI. Unless of course they are decompressed and nothing more is causing any secondary problems.

Still though this sounds incredible.

Max · 07-25-2005, 04:33 PM

Potential Treatment of Paralysis and Brain Disease

Libraries
Medical News Keywords
PARALYSIS ALZHEIMERS ALZHEIMER'S BRAIN DISEASE ALS KDI TRI-PEPTIDE TRI PEPTIDE GLUTAMATE UNIVERSITY OF HELSINKI PARALYZED RATS JOHNNIE B. BYRD JOHNNIE BYRD ALZHEIMER'S CENTER AND RESEARCH INSTITUTE Contact Information

Available for logged-in reporters onlyDescription

New research shows that a naturally-produced protein, KDI tri-peptide, can block the damaging effects of glutamate, a substance that is released by the body in response to CNS trauma and neurodegenerative disorders.

Newswise — A study released today could reveal the key to treating nearly 140 million people worldwide who suffer from spinal cord injuries, Alzheimer’s disease, ALS and other devastating neurological diseases.

The study, published in the online version of the Journal of Neuroscience Research, shows how a protein called KDI tri-peptide (KDI) can block the harmful effects of a substance called glutamate that is present in all degenerative brain diseases and spinal cord injuries, causing permanent cell death and preventing the repair of damaged nerve connections. Glutamate is produced as part of the body’s natural reaction to central nervous system damage.

In the new study, researchers at the Brain Laboratory at the University of Helsinki (www.brainlab.fi) and at the Johnnie B. Byrd, Sr., Alzheimer’s Center & Research Institute in Tampa, Fla., show KDI to be a potent and wide-ranging blocker of glutamate’s damaging chemical processes. It therefore has a tremendous ability to protect the brain and spinal cord from cell death and even enable regrowth.

Human clinical trials are expected to begin as soon as next year. No toxic side effects have been seen in studies so far, and the Finnish researchers do not expect any since KDI occurs naturally in the human body, including in the central nervous system. An added advantage is that KDI can be easily synthesised, therefore avoiding the problems associated with human cell donation.

Paralysis reversal in rats offered clues to wide-ranging applications

The new findings follow from previous studies in which KDI, when injected into the spines of paralyzed rats, produced dramatic results. The rats were able to bear weight and walk again after only 3 months. Further laboratory experiments showed that KDI also had the ability to promote regrowth of nerves in damaged areas and to prevent brain cell death. These results paved the way for new research with human cells.

In the new study, Dr. Päivi Liesi, M.D., Ph.D., and her research team applied KDI to human brain cells in the laboratory to see if KDI’s extraordinary ability to prevent nerve cell death and promote regeneration could be connected to its unexpected effect on the glutamate system. The study concludes that KDI is able to block various forms of glutamate function – leading researchers to believe that it may have wide-ranging applications.

“The wider significance of this research is that KDI treatment may become the first natural and targeted therapy for people with central nervous system injuries resulting in paralysis and a range of diseases such as Alzheimer’s and ALS, for which there are currently no cures,” said Dr. Liesi, head of the Brain Laboratory and a former visiting scientist at the National Institutes of Health.

New approach could fast-track to real results

Dr. Liesi’s long-term focused research has built upon an original discovery by George Martin, Ph.D., former scientific director for the National Institute on Aging at the National Institutes of Health. Dr. Martin first discovered the molecule known as laminin that KDI is derived from. Dr. Liesi identified laminin’s role in the nervous system and was able to isolate KDI from the larger molecule. After intensive study of its effects in the central nervous system, she began to recognise KDI’s enormous therapeutic potential.

http://www.newswise.com/articles/view/513180/

"I am excited by the potential clinical uses of KDI and by the prospect of clinical testing," said Dr. Victor Krauthamer, Ph.D., a former research collaborator of Dr. Liesi, speaking as an independent scientist. Dr. Krauthamer also is a research scientist at the U.S. Food and Drug Administration, Center for Devices and Radiological Health. "If these results play out in further trials, and there is a true treatment for a variety of currently untreatable neurological diseases, this could be one of the greatest discoveries in treating neurological conditions in the last 50 years."

Dr. Liesi conducts her current research in close collaboration with the Johnnie B. Byrd, Sr., Alzheimer’s Center & Research Institute in Tampa, Fla. The Byrd Institute is dedicated to helping and coordinating research, as well as building national and international collaborations. The goal of this productive international collaboration is to transform research results into practical clinical applications as quickly as possible, delaying the disease’s onset, and ultimately slowing or even halting the disease’s progression. Visit http://www.floridaalz.org for more details about the Byrd Institute’s ongoing efforts.

Details of Dr. Liesi’s research and further information can be found at http://www.brainlab.fi, a site affiliated with the University of Helsinki. The University is one of the centers of excellence among universities in Europe, concentrating on high-level scientific research and researcher education. The results produced through the research and teaching carried out at the University are widely acclaimed worldwide.

Rollin Rick · 07-25-2005, 05:10 PM

Woo Hoo,

Schmeky · 07-25-2005, 05:18 PM

Dr. Y,

Is this something that could take the place of chondrotinase (sp)?

Wonder if someone affiliated with University of Helsinki could attend the HKU-SCI symposium in December and represent KDI?

China alone could be a huge market for this product.

It's difficult for me to imagine how a single modality (KDI) could restore sunstantial function, especially in chronics.

Malibu · 07-26-2005, 02:12 PM

What exactly is the possible results from a clinical trial next year. Is this a great finding towards our cure?

Any thoughts please.

07-25-2005, 01:15 PM	#1
Max Senior Member Join Date: Jul 2001 Location: Montreal,Province of Quebec, CANADA Posts: 15,036	Nerve damage repair agent hope Nerve damage repair agent hope KDI may help with Alzheimer's and other brain diseases Scientists say they have discovered a protein that could be injected to repair damaged nerves and brain cells. The protein, KDI tripeptide, works by blocking the harmful effects of a substance present in degenerative brain diseases and spinal cord injuries. By blocking this substance, called glutamate, KDI prevents permanent cell death and helps the body heal itself. The Finnish work from the University of Helsinki will be published online by the Journal of Neuroscience Research. Human trials So far the researchers have tested KDI in the lab on animals and nerve cells from humans. http://news.bbc.co.uk/1/hi/health/4707023.stm __________________ http://stores.ebay.com/MAKSYM-Variety-Store

07-25-2005, 01:59 PM	#5
Sue Pendleton Moderator Join Date: Jul 2001 Location: Maryland USA Posts: 7,442	"It therefore has a tremendous ability to protect the brain and spinal cord from cell death and even enable regrowth." Sounds like it may be usable for chronic ailments. I mean even people with Alzheimer's have lost a lot upstairs before they are normally diagnosed. Even to just stop the damage in so many cases will make many lives so much better: ALS, MS, Alzheimers, new cord injuries. But it does sound promising for chronics. __________________ Courage doesn't always roar. Sometimes courage is the quiet voice at the end of the day saying, "I will try again tomorrow."

07-25-2005, 02:29 PM	#6
Lindox Senior Member Join Date: Mar 2003 Location: USA Posts: 9,025	This is very interesting and exciting. Looks to me though that a patient might have to take this for the rest of their lives in the disease process types of problems..and maybe even in the acute SCI. Unless of course they are decompressed and nothing more is causing any secondary problems. Still though this sounds incredible. __________________ Life isn't about getting thru the storm but learning to dance in the rain.

07-25-2005, 04:33 PM	#7
Max Senior Member Join Date: Jul 2001 Location: Montreal,Province of Quebec, CANADA Posts: 15,036	Potential Treatment of Paralysis and Brain Disease Potential Treatment of Paralysis and Brain Disease Libraries Medical News Keywords PARALYSIS ALZHEIMERS ALZHEIMER'S BRAIN DISEASE ALS KDI TRI-PEPTIDE TRI PEPTIDE GLUTAMATE UNIVERSITY OF HELSINKI PARALYZED RATS JOHNNIE B. BYRD JOHNNIE BYRD ALZHEIMER'S CENTER AND RESEARCH INSTITUTE Contact Information Available for logged-in reporters onlyDescription New research shows that a naturally-produced protein, KDI tri-peptide, can block the damaging effects of glutamate, a substance that is released by the body in response to CNS trauma and neurodegenerative disorders. Newswise — A study released today could reveal the key to treating nearly 140 million people worldwide who suffer from spinal cord injuries, Alzheimer’s disease, ALS and other devastating neurological diseases. The study, published in the online version of the Journal of Neuroscience Research, shows how a protein called KDI tri-peptide (KDI) can block the harmful effects of a substance called glutamate that is present in all degenerative brain diseases and spinal cord injuries, causing permanent cell death and preventing the repair of damaged nerve connections. Glutamate is produced as part of the body’s natural reaction to central nervous system damage. In the new study, researchers at the Brain Laboratory at the University of Helsinki (www.brainlab.fi) and at the Johnnie B. Byrd, Sr., Alzheimer’s Center & Research Institute in Tampa, Fla., show KDI to be a potent and wide-ranging blocker of glutamate’s damaging chemical processes. It therefore has a tremendous ability to protect the brain and spinal cord from cell death and even enable regrowth. Human clinical trials are expected to begin as soon as next year. No toxic side effects have been seen in studies so far, and the Finnish researchers do not expect any since KDI occurs naturally in the human body, including in the central nervous system. An added advantage is that KDI can be easily synthesised, therefore avoiding the problems associated with human cell donation. Paralysis reversal in rats offered clues to wide-ranging applications The new findings follow from previous studies in which KDI, when injected into the spines of paralyzed rats, produced dramatic results. The rats were able to bear weight and walk again after only 3 months. Further laboratory experiments showed that KDI also had the ability to promote regrowth of nerves in damaged areas and to prevent brain cell death. These results paved the way for new research with human cells. In the new study, Dr. Päivi Liesi, M.D., Ph.D., and her research team applied KDI to human brain cells in the laboratory to see if KDI’s extraordinary ability to prevent nerve cell death and promote regeneration could be connected to its unexpected effect on the glutamate system. The study concludes that KDI is able to block various forms of glutamate function – leading researchers to believe that it may have wide-ranging applications. “The wider significance of this research is that KDI treatment may become the first natural and targeted therapy for people with central nervous system injuries resulting in paralysis and a range of diseases such as Alzheimer’s and ALS, for which there are currently no cures,” said Dr. Liesi, head of the Brain Laboratory and a former visiting scientist at the National Institutes of Health. New approach could fast-track to real results Dr. Liesi’s long-term focused research has built upon an original discovery by George Martin, Ph.D., former scientific director for the National Institute on Aging at the National Institutes of Health. Dr. Martin first discovered the molecule known as laminin that KDI is derived from. Dr. Liesi identified laminin’s role in the nervous system and was able to isolate KDI from the larger molecule. After intensive study of its effects in the central nervous system, she began to recognise KDI’s enormous therapeutic potential. http://www.newswise.com/articles/view/513180/ "I am excited by the potential clinical uses of KDI and by the prospect of clinical testing," said Dr. Victor Krauthamer, Ph.D., a former research collaborator of Dr. Liesi, speaking as an independent scientist. Dr. Krauthamer also is a research scientist at the U.S. Food and Drug Administration, Center for Devices and Radiological Health. "If these results play out in further trials, and there is a true treatment for a variety of currently untreatable neurological diseases, this could be one of the greatest discoveries in treating neurological conditions in the last 50 years." Dr. Liesi conducts her current research in close collaboration with the Johnnie B. Byrd, Sr., Alzheimer’s Center & Research Institute in Tampa, Fla. The Byrd Institute is dedicated to helping and coordinating research, as well as building national and international collaborations. The goal of this productive international collaboration is to transform research results into practical clinical applications as quickly as possible, delaying the disease’s onset, and ultimately slowing or even halting the disease’s progression. Visit http://www.floridaalz.org for more details about the Byrd Institute’s ongoing efforts. Details of Dr. Liesi’s research and further information can be found at http://www.brainlab.fi, a site affiliated with the University of Helsinki. The University is one of the centers of excellence among universities in Europe, concentrating on high-level scientific research and researcher education. The results produced through the research and teaching carried out at the University are widely acclaimed worldwide. __________________ http://stores.ebay.com/MAKSYM-Variety-Store

07-25-2005, 05:18 PM	#9
Schmeky Senior Member Join Date: Sep 2002 Location: West Monroe, LA, USA Posts: 3,167	Dr. Y, Is this something that could take the place of chondrotinase (sp)? Wonder if someone affiliated with University of Helsinki could attend the HKU-SCI symposium in December and represent KDI? China alone could be a huge market for this product. It's difficult for me to imagine how a single modality (KDI) could restore sunstantial function, especially in chronics. Last edited by Schmeky; 07-25-2005 at 05:18 PM. Reason: word omission

07-25-2005, 01:25 PM	#2
Jakstraw Member Join Date: Nov 2003 Posts: 30	Hold for release until 12:01 a.m. EDT Jul. 25. The information in this press release is EMBARGOED until 12:01 a.m. EST, Monday, July 25. AScribe Newswire is providing the release in advance as a courtesy to the media. ATTENTION: Medical, Science editors New Study Reveals Potential New Treatment of Paralysis, Brain Disease; Research From Brain Laboratory at University of Helsinki Suggests Wide-Ranging Treatment Applications for Millions With Spinal Cord Injuries, Alzheimer's Disease, ALS, Other Debilitating Illnesses HELSINKI, Finland, July 25 (AScribe Newswire) -- A study released today could reveal the key to treating nearly 140 million people worldwide who suffer from spinal cord injuries, Alzheimer's disease, ALS and other devastating neurological diseases. The study, published in the online edition of the Journal of Neuroscience Research, shows how a protein called KDI tri-peptide (KDI) can block the harmful effects of a substance called glutamate that is present in all degenerative brain diseases and spinal cord injuries, causing permanent cell death and preventing the repair of damaged nerve connections. Glutamate is produced as part of the body's natural reaction to central nervous system damage. In the new study, researchers at the Brain Laboratory at the University of Helsinki (www.brainlab.fi ) and at the Johnnie B. Byrd, Sr., Alzheimer's Center & Research Institute in Tampa, Fla., show KDI to be a potent and wide-ranging blocker of glutamate's damaging chemical processes. It therefore has a tremendous ability to protect the brain and spinal cord from cell death and even enable regrowth. Human clinical trials are expected to begin as soon as next year. No toxic side effects have been seen in studies so far, and the Finnish researchers do not expect any since KDI occurs naturally in the human body, including in the central nervous system. An added advantage is that KDI can be easily synthesised, therefore avoiding the problems associated with human cell donation. PARALYSIS REVERSAL IN RATS OFFERED CLUES TO WIDE-RANGING APPLICATIONS The new findings follow from previous studies in which KDI, when injected into the spines of paralyzed rats, produced dramatic results. The rats were able to bear weight and walk again after only 3 months. Further laboratory experiments showed that KDI also had the ability to promote regrowth of nerves in damaged areas and to prevent brain cell death. These results paved the way for new research with human cells. In the new study, Dr. Pdivi Liesi, M.D., Ph.D., and her research team applied KDI to human brain cells in the laboratory to see if KDI's extraordinary ability to prevent nerve cell death and promote regeneration could be connected to its unexpected effect on the glutamate system. The study concludes that KDI is able to block various forms of glutamate function - leading researchers to believe that it may have wide-ranging applications. "The wider significance of this research is that KDI treatment may become the first natural and targeted therapy for people with central nervous system injuries resulting in paralysis and a range of diseases such as Alzheimer's and ALS, for which there are currently no cures," said Dr. Liesi, head of the Brain Laboratory and a former visiting scientist at the National Institutes of Health. NEW APPROACH COULD FAST-TRACK TO REAL RESULTS Dr. Liesi's long-term focused research has built upon an original discovery by George Martin, Ph.D., former scientific director for the National Institute on Aging at the National Institutes of Health. Dr. Martin first discovered the molecule known as laminin that KDI is derived from. Dr. Liesi identified laminin's role in the nervous system and was able to isolate KDI from the larger molecule. After intensive study of its effects in the central nervous system, she began to recognise KDI's enormous therapeutic potential. "One of the wonderful things about this is that Dr. Liesi's discoveries are ready now for prime-time testing in patients. We do not have to go through a long drug development procedure that might take 10 years," said Dr. Martin. "This represents a new approach and one with considerable promise, particularly because it could be applied and tested rapidly with a variety of disorders. The ability to treat degenerative brain diseases and spinal cord injuries with a substance that naturally occurs in the body is revolutionary." "I am excited by the potential clinical uses of KDI and by the prospect of clinical testing," said Dr. Victor Krauthamer, Ph.D., a former research collaborator of Dr. Liesi, speaking as an independent scientist. Dr. Krauthamer also is a research scientist at the U.S. Food and Drug Administration, Center for Devices and Radiological Health. "If these results play out in further trials, and there is a true treatment for a variety of currently untreatable neurological diseases, this could be one of the greatest discoveries in treating neurological conditions in the last 50 years." Dr. Liesi conducts her current research in close collaboration with the Johnnie B. Byrd, Sr., Alzheimer's Center & Research Institute in Tampa, Fla. The Byrd Institute is dedicated to helping and coordinating research, as well as building national and international collaborations. The goal of this productive international collaboration is to transform research results into practical clinical applications as quickly as possible, delaying the disease's onset, and ultimately slowing or even halting the disease's progression. Visit http://www.floridaalz.org for more details about the Byrd Institute's ongoing efforts. Details of Dr. Liesi's research and further information can be found at http://www.brainlab.fi, a site affiliated with the University of Helsinki. The University is one of the centers of excellence among universities in Europe, concentrating on high-level scientific research and researcher education. The results produced through the research and teaching carried out at the University are widely acclaimed worldwide

07-25-2005, 01:33 PM	#3
ip Senior Member Join Date: Jul 2001 Posts: 317	Anybody know if this is a significant study? The descriptions are glowing, so of course that gives me hope. Will this work for chronics?????

07-25-2005, 01:49 PM	#4
manouli Senior Member Join Date: Nov 2004 Location: florida Posts: 6,258	This is great news! Hey guys please tell me if you know that this will not only works when they apply it as soon after spinal cord injury? I want to try it right way. cross our fingers.manouli.

07-25-2005, 05:10 PM	#8
Rollin Rick Senior Member Join Date: Nov 2002 Location: B ville, New York, USA Posts: 767	Woo Hoo,

07-26-2005, 02:12 PM	#10
Malibu Senior Member Join Date: Dec 2004 Posts: 365	What exactly is the possible results from a clinical trial next year. Is this a great finding towards our cure? Any thoughts please.

Thread Tools
Show Printable Version Email this Page
Display Modes
Linear Mode Switch to Hybrid Mode Switch to Threaded Mode

Similar Threads
Thread	Thread Starter	Forum	Replies	Last Post
Spinal repair pioneer to speak in NY on 20th Jan	skode	Cure	17	01-20-2005 05:00 AM
Nerve cells 'guided' to repair spinal damage	patecatl	Cure	2	08-17-2004 07:27 AM
New horizons of nerve repair	Jeremy	Cure	3	07-26-2002 12:25 PM
Living Rings Made from Nerve Cells	Max	Cure	7	01-16-2002 06:15 PM
Nerve Damage? Just Glue It!	Birde	Cure	1	08-08-2001 11:08 AM